Dr. Weiwen Ying is Synta Fellow at Synta Pharmaceuticals (Nasdaq SNTA) in Lexington MA. He initiated and championed the discovery and development of ganetespib, an Hsp90 inhibitor, which is being evaluated in multiple clinical trials including a Phase III trial in lung cancer. As a prolific drug hunter, his experience in drug development ranges from conception of scientific ideas to managing relations with physicians and academic collaborators. Dr. Ying has published >20 peer-review journal articles and also has >30 issued or pending patents. Recently Weiwen and his colleague have developed the HDC (Hsp90-inhibitor Drug Conjugates) platform technology which has tremendous potential in creating an exciting, new class of anti-cancer therapies.
Prior to joining Synta in 2000, Dr. Ying was a postdoctoral fellow at SUNY Stony Brook and Yale University. He obtained Ph.D. in Organic Chemistry from Clemson University and M.S. from Shanghai Institute of Organic Chemistry, Chinese Academy of Science. He received his undergraduate degree from Sun Yat-sen University in Guangzhou, China.